VYGR

SEC source: 0001104659-25-016510 · tm257355-1_4seq.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,500

F1 · shares: Consists of shares of common stock issuable under an aggregate of 51,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016520 · tm257355-5_4seq1.xml · derivative · entry 3

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,000

Underlying: Common Stock · 290,000 shares

Expires 2035-02-21

F4 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016520 · tm257355-5_4seq1.xml · nonDerivative · entry 2

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 441,816

F3 · shares: Consists of shares of common stock issuable under an aggregate of 145,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016516 · tm257355-4_4seq1.xml · derivative · entry 3

Swartz Robin · CIK 0001909636 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 142,500 shares

Expires 2035-02-21

F4 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016516 · tm257355-4_4seq1.xml · nonDerivative · entry 2

Swartz Robin · CIK 0001909636 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,647

F3 · shares: Consists of shares of common stock issuable under an aggregate of 71,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016515 · tm257355-3_4seq1.xml · derivative · entry 2

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Common Stock · 83,000 shares

Expires 2035-02-21

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016515 · tm257355-3_4seq1.xml · nonDerivative · entry 1

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,143

F1 · shares: Consists of shares of common stock issuable under an aggregate of 41,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016522 · tm257355-6_4seq1.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,718

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.39, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-016520 · tm257355-5_4seq1.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,816

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.32, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-016516 · tm257355-4_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,397

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.33, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-012200 · tm256369-4_4seq1.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,023

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-012198 · tm256369-3_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,291

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-012196 · tm256369-2_4seq1.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 308,518

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Includes 2,323 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.

SEC source: 0001104659-25-012195 · tm256369-1_4seq1.xml · nonDerivative · entry 1

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,643

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-003772 · tm253408-1_4seq1.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,436

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.05 to $5.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001104659-25-003773 · tm253408-2_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · COO & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,241

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.05 to $5.23, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001104659-24-131725 · tm2431995-1_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · COO&CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,328

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.70, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · balance_after: Includes 1,824 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan on June 28, 2024.

SEC source: 0001104659-24-105885 · tm2425529-1_4seq1.xml · nonDerivative · entry 1

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,001

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $5.88, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-105438 · tm2425390-1_4seq1.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is October 1, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-24-078547 · tm2419082-2_4seq1.xml · derivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-07-08

F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-24-069664 · tm2416702-6_4seq1.xml · derivative · entry 1

Onyia Jude · CIK 0001894425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069667 · tm2416702-9_4seq1.xml · derivative · entry 1

Vitale Nancy · CIK 0001823262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069666 · tm2416702-8_4seq1.xml · derivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069665 · tm2416702-7_4seq1.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069662 · tm2416702-5_4seq1.xml · derivative · entry 1

MACKEY CATHERINE J · CIK 0001645330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069659 · tm2416702-4_4seq1.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069658 · tm2416702-3_4seq1.xml · derivative · entry 1

Higgins Michael J · CIK 0001478521 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069656 · tm2416702-2_4seq1.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-069650 · tm2416702-1_4seq1.xml · derivative · entry 1

Colon Grace · CIK 0001780354 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0001104659-24-043107 · tm2410775-2_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,004

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.01, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-043104 · tm2410775-1_4seq1.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,839

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.71 to $10.02, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-043111 · tm2410775-3_4seq1.xml · nonDerivative · entry 1

Ferguson Toby · CIK 0002015616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is April 1, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-24-039117 · tm249758-2_4seq1.xml · derivative · entry 1

Ferguson Toby · CIK 0002015616 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2034-03-25

F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-24-026554 · tm246990d1_4.xml · nonDerivative · entry 2

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,627

F3 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F3 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

SEC source: 0001104659-24-026562 · tm246990-4_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,361

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.36 to $7.52, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-026561 · tm246990-3_4seq1.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,954

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.55, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-026556 · tm246990-2_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,669

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-026554 · tm246990d1_4.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,992

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.76, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-024993 · tm246517-4_4seq1.xml · derivative · entry 2

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2034-02-09

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024993 · tm246517-4_4seq1.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,594

F1 · shares: Consists of shares of common stock issuable under an aggregate of 38,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024998 · tm246517-5_4seq1.xml · derivative · entry 2

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,000

Underlying: Common Stock · 62,000 shares

Expires 2034-02-09

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024998 · tm246517-5_4seq1.xml · nonDerivative · entry 1

Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,000

F1 · shares: Consists of shares of common stock issuable under an aggregate of 31,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024989 · tm246517-3_4seq1.xml · derivative · entry 2

Swartz Robin · CIK 0001909636 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-02-09

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024989 · tm246517-3_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,327

F1 · shares: Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024982 · tm246517-2_4seq1.xml · derivative · entry 2

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Common Stock · 260,000 shares

Expires 2034-02-09

F3 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024982 · tm246517-2_4seq1.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,987

F1 · shares: Consists of shares of common stock issuable under an aggregate of 130,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

F2 · balance_after: Includes 3,369 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.

SEC source: 0001104659-24-024981 · tm246517-1_4seq1.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-02-09

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024981 · tm246517-1_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,433

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-005244 · tm243664-1_4seq1.xml · nonDerivative · entry 1

Carter Todd Alfred · CIK 0001944011 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,094

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.27, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-005247 · tm243664-2_4seq1.xml · nonDerivative · entry 1

Swartz Robin · CIK 0001909636 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,327

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.27, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Includes 3,253 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.